Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $25,752 | $284 | $141 | $132 |
Gross Profit | 24,225 | 284 | 141 | -188 |
EBITDA | -101,130 | -118,695 | -101,318 | -113,627 |
EBIT | -101,473 | -118,812 | -101,439 | -113,747 |
Net Income | -101,209 | -127,119 | -104,901 | -120,355 |
Net Change In Cash | 25,752 | 284 | 141 | 132 |
Free Cash Flow | -93,143 | -106,630 | -119,677 | -23,994 |
Cash | 172,860 | 164,986 | 176,346 | 212,382 |
Basic Shares | 113,407 | 107,884 | 102,211 | 84,803 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $70,849 | $302 | $314 | $1,772 |
Gross Profit | 70,849 | 302 | 314 | 1,772 |
EBITDA | -337,193 | -266,363 | -235,365 | -129,133 |
EBIT | -337,653 | -266,903 | -235,887 | -129,388 |
Net Income | -342,601 | -269,949 | -237,734 | -129,874 |
Net Change In Cash | 70,849 | 302 | 314 | 1,772 |
Cost of Revenue | 113,280 | |||
Free Cash Flow | -276,886 | -232,830 | -185,068 | -94,635 |
Cash | 212,382 | 99,594 | 102,827 | 155,579 |
Basic Shares | 84,803 | 67,886 | 44,755 | 32,087 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.81 |
2026-06-30 | -$1.05 |
2026-03-31 | -$0.90 |
2025-12-31 | -$1.08 |